Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday | 2 | Benzinga.com | ||
Mi | Baird starts Alumis coverage with Outperform, $25 target | 2 | Investing.com | ||
17.10. | Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside | 11 | Benzinga.com | ||
17.10. | Alumis (NASDAQ:ALMS) Shares Gap Up - Time to Buy? | 1 | MarketBeat | ||
17.10. | H.C. Wainwright vergibt Kaufempfehlung für Alumis-Aktie | 1 | Investing.com Deutsch | ||
17.10. | H.C. Wainwright sets Buy rating on Alumis stock | 1 | Investing.com | ||
17.10. | H.C. Wainwright sets Buy rating on Alumis stock, cites TYK2 inhibitor | 4 | Investing.com | ||
17.10. | H.C. Wainwright setzt Kaufempfehlung für Alumis-Aktie, hebt TYK2-Inhibitor hervor | 1 | Investing.com Deutsch | ||
27.09. | Alumis reports progress in psoriasis treatment trial | 2 | Investing.com | ||
27.09. | Alumis meldet Fortschritte bei Psoriasis-Behandlungsstudie | 4 | Investing.com Deutsch | ||
27.09. | Alumis Inc.: Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study | 3 | GlobeNewswire (USA) | ||
03.09. | Alumis Inc.: Alumis to Participate in Upcoming September Investor Conferences | 1 | GlobeNewswire (USA) | ||
14.08. | Alumis reports Q2 results | 1 | Seeking Alpha | ||
13.08. | ALUMIS INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
13.08. | ALUMIS INC. - 8-K, Current Report | 1 | SEC Filings | ||
13.08. | Alumis Inc.: Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements | 101 | GlobeNewswire (Europe) | - Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis - - Initiated Phase 1 clinical trial for A-005 in healthy participants - - Completed IPO... ► Artikel lesen | |
29.07. | Alumis Inc.: Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis | 146 | GlobeNewswire (Europe) | - Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission - - Pivotal Phase 3 program supported by positive Phase 2 STRIDE clinical data as well... ► Artikel lesen | |
24.07. | Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation | 1 | Benzinga.com | ||
18.07. | ALUMIS INC. - 8-K, Current Report | 1 | SEC Filings | ||
09.07. | Alumis resumes decline a day after first positive session post IPO | 1 | Reuters |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 8,100 | +13,37 % | Evotec Aktie: Wochen der Wahrheit? | Bei der Evotec Aktie haben am Donnerstag und Freitag zum einen Gewinnmitnahmen nach dem jüngsten Kursanstieg das Bild geprägt. Aber - zumindest am Donnerstag - blieben zudem Rückkäufe der Evotec Aktie... ► Artikel lesen | |
QIAGEN | 40,170 | +1,11 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
VIKING THERAPEUTICS | 58,46 | -14,18 % | AKTIONÄR-Depotwert Gubra: Bald wie Viking Therapeutics? | Die Aktie von Viking Therapeutics hat in der Vorwoche massive Kursgewinne verzeichnet. Vor allem die Aussicht auf weiteren Studiendaten zum Adipositas-Hoffnungsträger VK2735 Anfang November sowie die... ► Artikel lesen | |
BIONTECH | 102,20 | -0,20 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
ADMA BIOLOGICS | 19,250 | +0,03 % | ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co. | ||
DISC MEDICINE | 59,50 | +28,37 % | Disc Medicine Inc: Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval | Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,55 | -0,22 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,000 | +7,58 % | Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter... ► Artikel lesen | |
HARMONY BIOSCIENCES | 33,040 | -0,24 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,990 | +6,86 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
DYNE THERAPEUTICS | 28,870 | +0,21 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
ARCELLX | 87,83 | +2,59 % | Arcellx (ACLX) Surged in Q3. Here's Why | ||
BEAM THERAPEUTICS | 24,750 | +8,55 % | Beam Therapeutics' Earnings: A Preview | ||
RECURSION PHARMACEUTICALS | 6,655 | +3,42 % | Peering Into Recursion Pharmaceuticals' Recent Short Interest | ||
NEUMORA THERAPEUTICS | 11,690 | +3,73 % | Neumora Therapeutics, Inc.: Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 |